The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva ...

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

Teva Pharmaceuticals has launched the first generic GLP-1 drug for weight loss in adults and adolescents; a lower-cost ...

The FDA has approved the first generic liraglutide indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.